GL1X · GenesisL1 explorer

MolNFT v1 · #103977 · protein

Structure of P450SKY (CYP163B3), a cytochrome P450 from skyllamycin biosynthesis in complex with a peptidyl carrier protein domain

4PWV · P450 monooxygenase: “Structure of P450SKY (CYP163B3), a cytochrome P450 from skyllamycin biosynthesis in complex with a peptidyl…”. X-ray diffraction, 2 ligands (HEM, KH4), 3 pockets (best druggability 0.85). MolNFT v1 #103977 on…

PDB
4PWV
Type
protein
Length
486 residues
Chains
2
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
P450 monooxygenase; Peptide synthetase
EC
1.14.14.1
UniProt
F2YRY7, F2YRY5
Ligands
HEM, KH4
Pockets
3 · best druggability 0.85

Structure

x-ray diffraction · 2 distinct chains · 51% helix, 11% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
AP450 monooxygenase (EC 1.14.14.1)protein41150% helix, 13% strandF2YRY7
BPeptide synthetaseprotein7556% helix, 0% strandF2YRY5

Ligands and binding sites

  • HEM · Protoporphyrin IX containing Fe · ligand · chains A
  • KH4 · S-[2-({N-[(2R)-2-hydroxy-3,3-dimethyl-4-(phosphonooxy)butanoyl]-beta-alanyl}amino)ethyl] 1H-imidazole-4-carbothioate · ligand · chains A, B

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

3 pockets found on a 1 Å grid, 3 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
16420.850.8968HEM, KH4
23660.670.8130empty
32330.550.7828empty

Interfaces

1 interface between chains.

  • A–B · 701 Ų buried · 4 hydrogen bonds · protein-protein

Modifications

Observed in the structure: 7 modified, 1 covalent (engineered, covalent ligand).

Compared structures

  • 4PWV · Structure of P450sky (CYP163B3), a cytochrome P450 from skyllamycin biosynthesis in… · the same entry in another collection · chain A against A, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.